Diagnosis and Treatment of Chronic Chlamydia Pneumoniae

Clinical Background

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects 2.5 million people worldwide. Current treatments for MS have adverse effects and are poorly tolerated. The cause of MS is not known, but there is considerable evidence that suggests infectious agents play a role in the debilitating disease.

It has been shown that the presence of one such infectious agent, Chlamydia, indicates the presence of MS and that treatment of Chlamydia improves or sustains neurological function. Present treatment of Chlamydia includes a short course of a single antibiotic. Such treatment often results in relapse as Chlamydia is often present as a latent species that will later re-infect cells.

Technology Description

• Provides a method of diagnosing MS by testing for the presence of Chlamydia.

• Provides a method of individualized treatment: various combinations of agents directed at different phases of the chlamydial life cycle allowing for rapid and total eradication of species based on factors such as degree of infection and side effects.

• Provides a method of monitoring the eradication of Chlamydia during treatment by detecting the pathogens that are viable but not currently replicating, thus preventing relapse after therapy.

• Provides a kit with ingredients for the therapeutic agents that can be individualized for each patient based on their preferred combination treatment.

Technology Summary

The technology provides a method for diagnosis of MS by detection of Chlamydia and treatment of MS by total eradication of Chlamydia. This technology provides for eradication of Chlamydia by a novel treatment of combining various anti-chlamydial agents directed at different phases of the chlamydial life cycle.

Intellectual Property Status

Over 10 issued US patents and additional Foreign patents protect this technology.

U.S. Patent # 7,094,397: Methods and reagents for the treatment of multiple sclerosis

U.S. Patent # 6,579,854: Diagnosis and management of infection caused by chlamydia

U.S. Patent # 6,340,463: Identification of antigenic peptide sequences

U.S. Patent # 6,258,532: Method for in vitro susceptibility testing of chlamydia

U.S. Patent # 6,562,582: Chlamydia-free cell lines and animals

U.S. Patent # 6,710,033: Methods and treatment of multiple sclerosis

William MitchellCharles StrattonSubramaniam SriramJason BannonSong-Yi YaoAsa Ljunggren-Rose
Licensing manager: 
Janis Elsner

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter